Table 4 Comparison of abnormal liver function indexes in the Omicron BA5.2 and prototype patients

ALT / ( U·L^-1 )

129.80 ± 131.60

66.68 ± 39.68

2.208

0.030

 1–2 ULN

34 (21.7%)

17 (8.5%)

12.300

< 0.001

 > 2 ULN

45 (28.7%)

5 (2.5%)

49.710

< 0.001

AST / ( U·L^-1 )

81.18 ± 40.54

53.11 ± 12.79

2.975

0.004

 1–2 ULN

20 (12.7%)

16 (8.0%)

2.132

0.144

 > 2 ULN

35 (22.3%)

3 (1.5%)

39.770

< 0.001

ALB / ( g·L^-1 )

36.70 ± 4.64

42.97 ± 2.24

17.730

< 0.001

 ≥ 35

93 (59.2%)

199 (100.0%)

98.900

< 0.001

 < 35

64 (40.7%)

0 (0.0%)

98.900

< 0.001

TB / ( umol·L^-1 )

31.09 ± 19.25

25.25 ± 4.60

1.082

0.283

 1–2 ULN

46 (29.3%)

13 (5.5%)

32.900

< 0.001

 > 2 ULN

8 (5.1%)

0 (0.0%)

10.370

0.001

GGT/ ( U·L^-1 )

184.70 ± 206.40

103.20 ± 63.14

2.110

0.038

 1–2 ULN

25 (15.9%)

20 (10.1%)

2.742

0.098

 > 2 ULN

36 (22.9%)

10 (5.0%)

25.100

< 0.001

LDH/ ( U·L^-1 )

538.10 ± 1074.00

278.30 ± 28.68

0.416

0.679

 1–2 ULN

52 (33.1%)

3 (1.5%)

67.150

< 0.001

 > 2ULN

20 (12.7%%)

0 (0.0%)

26.860

< 0.001